Blocking AR signaling can sensitize the tumor-bearing host to effective checkpoint blockade by directly enhancing CD8 T cell function, preventing T cell exhaustion, and improving responsiveness to PD-1 targeted therapy via increased IFNγ expression (43). Here, CD8A is linked to neoplasm.